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Vitiligo is a common depigmentation disorder thought
to result from autoimmune destruction of melanocytes.
Recent studies suggest a role for cell-mediated immune
responses to melanocyte di¡erentiation antigens, in-
cluding gp100, MelanA/MART-1, and tyrosinase, in
vitiligo pathogenesis.This study investigatedTcell reac-
tivity to MelanA/MART-1, tyrosinase, and gp100, in
HLA-A2-positive patients with vitiligo. Melanocyte-
speci¢c T cell responses were measured ex vivo via en-
zyme-linked immunospot assay following stimulation
with MelanA/MART-1, tyrosinase, and modi¢ed gp100
epitopes. Antigen-speci¢c T lymphocyte reactivity to
gp100 peptides was seen in 15 of 17 (88%) patients, with
many demonstrating very high reactivity at levels com-
parable with those observed with common recall anti-
gens. Reactivity to gp100 was noted to be associated
with disease activity. Antigen-speci¢c T lymphocyte
reactivity to MelanA/MART-1 and tyrosinase peptides
was not observed ex vivo in our patients, and only one
patient demonstrated responses to MelanA/MART-1
and tyrosinase peptides following in vitro re-stimula-
tion. Our ¢ndings implicate T cell reactivity to gp100
in patients with active disease and support the concept
of an immunopathologic mechanism in vitiligo, in
which cell-mediated responses to normal melanocyte anti-
gens play a crucial part. Key words: CD8þ Tcells/enzyme-
linked immunospot assay/melanocyte antigens/melanoma/
pigmentary disorders. J Invest Dermatol 121:550 ^556, 2003
V
itiligo is a common acquired depigmentation disor-
der characterized by loss of epidermal melanocytes
(Kovacs, 1998). Although the precise etiology of vi-
tiligo is unknown, an autoimmune mechanism has
been proposed (Kemp et al, 2001). This stems from
the fact that many vitiligo patients also exhibit other autoim-
mune disorders, such as autoimmune thyroiditis, Addison’s dis-
ease, alopecia areata, pernicious anemia, and type I diabetes
(Kemp et al, 2001). Further support for this hypothesis is provided
by the ¢nding that many vitiligo patients have antibodies to mel-
anocytes (Naughton et al, 1983; Bystryn and Naughton, 1985;
Song et al, 1994; Kemp et al, 1998), and the extent of depigmenta-
tion is correlated with the incidence and level of anti-melanocyte
antibodies (Naughton et al, 1983). Moreover, patients may respond
to immunosuppressive treatments, such as psoralen with ultra-
violet A radiation (Parrish et al, 1976), topical corticosteroids
(Kumari, 1984), and cytotoxic drugs (Tsuji and Hamada, 1983).
Recent evidence has emerged for a role for cell-mediated im-
munity in vitiligo pathogenesis. In¢ltrating activated T lympho-
cytes have been observed at the periphery of vitiligo lesions
(Badri et al, 1993). A recent immunopathologic study of lesional
skin of vitiligo patients noted a high frequency of cutaneous lym-
phocyte antigen-positive activated cytotoxic T cells clustered in
perilesional skin in the vicinity of disappearing melanocytes
(van den et al, 2000). Melanocytes in close proximity to activated
lymphocytes focally expressed HLA-DR and intercellular adhe-
sion molecule-1, suggesting a major role for skin-homing T cells
in melanocyte death (van den et al, 2000). An increased level of
soluble interleukin (IL)-2 receptor (Caixia et al, 1999; Yeo et al,
1999), IL-6, and IL-8 (Yu et al, 1997), has been observed in vitiligo
patients, which also suggests that T cell activation may be a com-
ponent in vitiligo pathogenesis. Further evidence for a part played
by cytotoxic T cells (CTL) in vitiligo stems from studies of mel-
anoma patients.Vitiligo is found more frequently in patients with
metastatic melanoma (Nordlund et al, 1983; Bystryn et al, 1987;
Cui and Bystryn, 1995; Cavallari et al, 1996) and is associated with
an improved prognosis (Nordlund et al, 1983; Bystryn et al, 1987).
Vitiligo-like depigmentation has been observed following suc-
cessful immunotherapy of melanoma (Rosenberg and White,
1996; Nestle et al, 1998; van Elsas et al, 1999;Yee et al, 2000), includ-
ing high-dose IL-2 therapy (Rosenberg et al, 1996) and infusions
of peptide-pulsed dendritic cells (Nestle et al, 1998) and MelanA/
MART-1-speci¢c CTL clones (Yee et al, 2000). Furthermore, cy-
totoxic T cells generated from melanoma tissue also recognize
di¡erentiation antigens expressed by normal melanocytes
(Kawakami et al, 2000;Yee et al, 2000), suggesting a link between
autoimmunity and tumor immunity.
The possibility that melanocyte di¡erentiation antigens repre-
sent the molecular targets of a cell-mediated autoimmune re-
sponse in vitiligo has recently been investigated. These antigens
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include melanosomal proteins, such as MelanA/MART-1, tyrosi-
nase, and gp100, involved in biosynthesis of melanin (Norlund
et al, 1983). Recent studies have noted a speci¢c cellular immune
response predominantly directed against the melanosomal pro-
tein Melan-A/MART-1 in HLA-A2-positive vitiligo patients
(Ogg et al, 1998; Lang et al, 2001; Palermo et al, 2001), where
CD8þ T cells displaying MelanA/MART-1-speci¢c reactivity
ex vivo were demonstrated in the peripheral blood of these pa-
tients. In this study we investigated T cell reactivity to MelanA/
MART-1, tyrosinase, and gp100, in vitiligo patients, in order to
elucidate the role of cell-mediated immunity in disease pathogen-
esis. Herein we show that T cell reactivity to the modi¢ed forms
of gp100 epitopes can be readily detected ex vivo in vitiligo pa-
tients with active disease, suggesting that a component of this
cell-mediated autoimmune disease is directed to the melanocyte
gp100 protein.We also show that there is an association of anti-
gp100 reactivity with the active disease state of individual patients
in our cohort of HLA-A2-positive individuals.
MATERIALS AND METHODS
Patients Study subjects consisted of 27 patients with nonsegmental
vitiligo each of whom had been seen at the Cosmetic Clinic at the
Sunnybrook and Women’s College Health Sciences Center Dermatology
Unit. Following informed consent, historical data were obtained via
direct interview, questionnaire, and chart review. Patients were questioned
regarding the progression of their vitiligo as well as their personal and
family history of vitiligo and associated autoimmune diseases, including
thyroiditis, alopecia areata, pernicious anemia, myasthenia gravis, and type
I diabetes. Patients were classi¢ed as having progressive disease if they had
developed new lesions within the previous 6 mo. A family history was
regarded as being positive if there was one or more ¢rst, second, or third
degree relatives a¡ected. Patients and blood samples were assigned a
number to ensure blinding of laboratory investigators to the subjects’
clinical characteristics. Immunologic analysis by patient number was
completed prior to amalgamation with historical data. This study was
approved by the Institutional Review board of Sunnybrook andWomen’s
College Health Sciences Center (SWCHSC), and all patients signed
informed consents before giving blood.
HLA-A2 typing HLA-A2-positive patients were identi¢ed by £ow
cytometry using £uorescein isothiocyanate conjugated allele-speci¢c
antibody BB7.2 (Parham and Brodsky, 1981). Of the total of 27 patients
screened for the study, 18 were found to be HLA-A2 positive and this
group constitutes the study population. Eight healthy asymptomatic
HLA-A2-positive individuals were also included as a control group.
Lymphocyte preparation Peripheral blood mononuclear cells (PBMC)
were isolated from 40 to 50mL heparinized blood samples by density
gradient centrifugation over Ficoll-Hypaque 1.077 (Amersham Pharmacia,
Sweden). PBMC were washed with Hank’s balanced salt solution (Gibco-
BRL Burlington, Ontario, Canada) and frozen in RPMI-1640 medium
(Gibco-BRL) containing 20% AB serum (Sigma Oakville, Ontario,
Canada) and 10% dimethyl sulfoxide and stored in liquid nitrogen until
analysis.
Peptide synthesis The following HLA-A2-restricted peptides were used
for stimulation in the ELISPOT assay. For gp100 protein: the modi¢ed
epitopes 209.2m (IMDQVPSFV) and 280.9v (YLEPGPVTV) (Parkhurst
et al, 1996); for MelanA/MART-1: AAGIGILTV (Coulie et al, 1994); and
for tyrosinase: YMDGTMSQV (Skipper et al, 1996). Also included were
GILGFVFTL (Gotch et al, 1987), the dominant epitope from in£uenza A
(Flu) matrix protein (MP), NLVPMVATV (Wills et al, 1996) from
cytomegalovirus (CMV) p65, and the HIV p17Gag protein derived
peptide SLYNTVATL (Parker et al, 1992). All peptides were synthesized at
Aventis Pasteur (Toronto, Canada), in an automated multiple peptide
synthesizer (MPS-396, Advanced ChemTech, Louisville, KY), using
standard Fmoc chemistry. The cleavage was performed on-line, using
the reagent K TFA/water/thioanisole/phenol/ethanedithiol, 82.5:5:5:5:2.5).
The crude peptides were precipitated with diethylethyl ether, washed
(3 diethyl ether), dissolved in 20% acetonitrile and lypholized. The
identities of the products were con¢rmed by ion spray mass spectroscopy.
ELISPOT assay Nitrocellulose 96 well plates (MAHA 45, Millipore,
Bedford, Massachusetts) were coated with 100 mL per well of human
interferon (IFN)-g speci¢c antibody 5 mg per mL (clone 1-D1K,
MABTECH, Stockholm, Sweden) in coating bu¡er (0.1 M Na2HPO4,
pH 9.0) overnight at 41C. Unbound antibody was removed by washing
three times with phosphate-bu¡ered saline. Nonspeci¢c sites on the plates
were blocked with 1% bovine serum albumin in phosphate-bu¡ered saline
for 1 h at room temperature. Plates were washed three times with
phosphate-bu¡ered saline and the appropriate number of responder
PBMC were added. Plates were incubated overnight at 371C, 5% CO2.
Cells were discarded and plates were washed three times with deionized
water, and ¢ve times with phosphate-bu¡ered saline/Tween. Biotinylated
anti-IFN-g antibody (clone 7-B6-1, MABTECH) was added in 100 mL
per well (1 mg per mL). Plates were then incubated for 3.5 h at room
temperature. This was followed by the addition of a 1:500 dilution of
extra avidin^alkaline phosphatase (Sigma) in 100 mL blocking bu¡er/
Tween added per well and plates were incubated for 1h at room
temperature. The plates were developed using NBT/BCIP phosphatase
substrate solution (Sigma) and blue spots were counted using an AID Inc.
ELISPOT Image Analyzer and software (Cell Technology Inc. Jessup,
MD).
Ex vivo ELISPOT assays to detect IFN-c secretion PBMC were
thawed, washed, and incubated overnight in AIM-V medium (Gibco-
BRL) containing 50 mM 2-mercaptoethanol (Sigma) at 371C in 5% CO2.
For the direct detection of IFN-g secretion, 1105 PBMC were added
directly to the ELISPOT plate with the appropriate peptides listed in the
¢gure legends. Plates were developed 18 h later. To attempt to allow
peptide speci¢c T cells to increase in numbers, PBMC were plated
in complete AIM-V medium (10% AB serum, Valley Biomedical,
[Winchester,VA] 50 mm 2-mercaptoethanol), at 1^2106 cells per well in
a 48 well plate. The next day, 10 mg per mL of peptides were added plus 10
ng per mL recombinant IL-7 (R&D Systems, Minneapolis, Minnesota).
Recombinant IL-2 (Chiron, Emeryville, California) was added on days 2
and 6 at 20 IU per mL. Cells were harvested 9 d after stimulation and
added to the ELISPOT plate at 1105 cells per well. For each peptide-
stimulated group, the same melanocyte-derived peptide was added to
wells in triplicate. To control for nonspeci¢c cell culture responses, a
known HLA-A2 binding peptide from the HIV GAG protein was added
to samples from each group. This served as a control from nonspeci¢c
responses. All peptides were added at a ¢nal concentration of 10 mg per mL.
Statistical testing TheWilcoxon signed-rank test was used to compare
responses between paired data. The Wilcoxon sum-of-ranks test for
comparing two unmatched samples was used for testing di¡erences in
ELISPOT ratios between di¡erent subgroups of study subjects. po0.05
was considered statistically signi¢cant.
RESULTS
Peptide-speci¢c CD8þ T lymphocyte reactivity to gp100
detected by ELISPOT assay in vitiligo patients The ex vivo
recall response to melanocyte peptide epitopes was measured in
vitiligo patient PBMC by stimulating cultures with the HLA-
A2-restricted peptides from MelanA/MART-1, tyrosinase, and
gp100. To optimize the detection of cell-mediated anti-
melanocyte activity to gp100, an admixture of both gp100
modi¢ed epitopes were added to the same culture wells.
Modi¢cation of the gp100 epitopes 209 to 217 and 280 to 288,
by substituting amino acids at the primary anchor residues for
peptide/major histocompatibility complex binding, has been
shown to increase major histocompatibility complex binding
and improve CD8 T cell speci¢c responses (Parkhurst et al, 1996).
Previous reports have shown that the use of the modi¢ed gp100
epitopes can reveal CD8 T cell responses in the peripheral blood
of patients with vitiligo (Palermo et al, 2001) and melanoma
(Nielsen et al, 2000). We chose to assay for melanocyte-speci¢c
immunity using a short-term ex vivo assay designed to optimize
the detection of cell-mediated anti-melanocyte activity without
the need of an in vitro re-stimulation step. In vitro re-stimulation
of PBMC cultures can result in the introduction of nonspeci¢c
T cell activation, which can mask peptide speci¢c responses. In
addition, culturing PBMC with peptides may drive primary
responses instead of measuring true recall responses to
previously seen antigen. Measurement of peptide-speci¢c
CD8þ T cell activity immediately ex vivo may more realistically
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re£ect the activation state of peptide-speci¢c CTL present in the
peripheral blood. As a measure of antigen-speci¢c T cell e¡ector
function, secretion of IFN-g was monitored to determine the
frequency of responding CD8þ T cells using the ELISPOT
assay. To provide a reference point for the magnitude of the T
cell response to melanocyte peptides, patient samples were also
screened for peptide-speci¢c responses to a mixture of CMV
and Flu peptides representing the immunodominant HLA-A2
epitopes. The admixture of both Flu and CMV epitopes was
done to gauge the overall capacity of T cells in the periphery to
produce IFN-g upon peptide stimulation immediately ex vivo.We
reasoned that as viral infection with either Flu or CMVgenerates
strong recall responses, their dominant epitopes would be good
markers to measure IFN-g produced by antigen-experienced
CTL.
To delineate reactivity of antigen-speci¢c CD8þ T cells to
melanocyte antigens in vitiligo patients, the number of spots
generated by ELISPOT assay to test peptides was compared with
the number of spots generated to control peptide for each patient.
The control peptide was tested as a measure of overall
background reactivity. To quantify reactivity to the melanocyte
peptides, a ratio was determined by dividing the number of
spots generated to test peptides on ELISPOT assay by the
number of spots generated to control peptide. A ratio of more
than 1.0 was indicative of reactivity to melanocyte peptides,
whereas a ratio of 1.0 or less indicated no peptide reactivity
(Table I). Signi¢cant reactivity to gp100 peptides relative to
control peptide was demonstrated in HLA-A2-positive vitiligo
patients (median ratio 3.33, percentile25^75 (1.5, 20.0), 95%
con¢dence interval (2.3812, 9.1057); p¼ 0.0001, one-sided signed-
rank test (Table I). Fifteen of 17 patients (88%) demonstrated
reactivity to gp100, with ratios greater than 1.0. Eight of 17
patients had at least a 4-fold greater reactivity above background
where the magnitude of the anti-gp100 response approached
or surpassed the level seen with the Flu/CMV combination.
Figure 1 depicts melanocyte peptide reactivity in a sample of
patients and is representative of the type of results generated in
our assay. Reactivity to gp100 was not demonstrated among
eight healthy HLA-A2-positive control donor PBMC (Fig 2).
Lack of peptide-speci¢c responses to MelanA/MART-1 and
tyrosinase In contrast to previous results (Ogg et al, 1998; Lang
et al, 2001; Palermo et al, 2001), we were unable to detect
signi¢cant ex vivo reactivity to the MelanA/MART-1 (mean of
ratios¼ 0.82, 95% con¢dence interval (0.50, 1.13); one-sided
signed-rank test, p¼ 0.1108) or tyrosinase (mean of ratios¼ 0.82,
95% con¢dence interval for ratio is (0.55, 1.09); one-sided signed-
rank test, p¼ 0.0858) peptides (Fig 1, Table I) among vitiligo
patients. Ratios of greater than 1.0 for both MelanA/MART-1
and tyrosinase peptides were seen in 28% (¢ve of 18) of patients,
suggesting that some low-level reactivity might be present. In
an attempt to enhance the reactivity to MelanA/MART-1 and
tyrosinase epitopes, four patients’ PBMC were cultured in vitro
for 9 d with IL-2 in hopes of expanding out low frequencies of
responding lymphocytes. As is shown in Fig 3 and Table II,
upon re-stimulation only patient 49 exhibited responses to
MelanA/MART-1 and tyrosinase, with ratios of 13.58 and 8.67,
respectively. In three of the four patients (patients 37, 40, 55), the
nonspeci¢c response was equal to or greater than the peptide-
speci¢c response. This suggests that some reactivity to MART-1
and tyrosinase may exist but at low levels and in a minority of
patients. No reactivity to MelanA/MART-1 or tyrosinase was
seen in eight healthy HLA-A2-positive donors (data not shown).
Association of disease activity and T cell reactivity to gp100
peptides We next tested to see if there was a positive association
between disease activity and T cell reactivity to melanocyte
antigens. Twelve of 18 (67%) HLA-A2-positive vitiligo patients
were classi¢ed as having ‘‘active’’ disease (i.e., new lesions within
the previous 6 mo) at the time of assessment. The remainder of
Table I. Clinical characteristics and melanocyte peptide-speci¢c CTL reactivity ex vivo in HLA-A2þ vitiligo patients
Patient characteristics Peptide-speci¢c CTL reactivitya
Patient Sex
Active
disease?
Other
autoimmune
disease?b
Family
history?
HIV control
peptide
Gp100 peptides
209.2m/
280.9v
Ratioc
for
Gp100
Tyrosinase
Peptide
Ratioc for
tyrosinase
MART-1
peptide
Ratioc for
MART-1
CMV/Flu
peptides
Ratioc for
CMV/Flu
2 F No Yes No 53 45 0.85 39 0.74 50 0.94 57 1.08
4 M No No No 3 4 1.33 4 1.33 1 0.33 0 0
5 F Yes No Yes 2 3 1.50 1 0.50 1 0.50 0 0
35 M No Yes Yes 3 7 2.33 6 2.00 5 1.67 5 1.67
37 M No No Yes 3 10 3.33 5 1.67 5 1.67 10 3.33
39 F Yes No Yes 5 7 1.40 3 0.60 3 0.60 91 18.2
40 F Yes No Yes 3 9 3.00 4 1.33 5 1.67 6 2.00
42 M Yes No No 16 NDd NDd 12 0.75 16 1.00 29 1.81
44 F Yes No Yes 18 90 5.00 8 0.44 18 1.00 163 9.06
45 M No Yes Yes 1 8 8.00 0 0.00 1 1.00 20 20.00
46 F Yes No Yes 2 45 22.50 2 1.00 0 0.00 46 23.00
47 F Yes No Yes 4 80 20.00 1 0.25 2 0.50 2 0.5
48 M Yes Yes Yes 2 64 32.00 1 0.50 0 0.00 1 0.5
49 F Yes No No 27 47 1.74 34 1.26 52 1.93 79 2.93
50 F Yes No Yes 3 67 22.33 1 0.33 1 0.33 89 29.67
53 F Yes No Yes 1 42 42.00 1 1.00 0 0.00 46 46.00
54 F Yes No Yes 14 61 4.36 3 0.21 3 0.21 3 0.21
55 M No Yes Yes 6 6 1.00 5 0.83 8 1.33 4 0.67
aShown is the number of spots seen on ELISPOT assay/1105 PBMC after ex vivo stimulation with melanocyte, HIV, and CMV/Flu peptide antigens.
bIncluding thyroiditis, alopecia areata, pernicious anemia, myasthenia gravis, and type I diabetes.
cPeptide ratios were derived by dividing the number of spots generated to test peptides on ELISPOT assay by the number of spots generated to HIV control peptide.
Note that 15 of 17 patients (88%) had gp100 reactivity ratios of greater than 1.0, and eight of 17 patients (47%) displayed reactivity to gp100 of at least 4 -fold above control
at levels comparable with those seen with the Flu/CMVcombination, corresponding to a high level of CTL reactivity to gp100 in HLA-A2þ vitiligo patients (po0.0001).
In contrast, reactivity ratios of 1.0 to 2.0 to MART-1 and tyrosinase peptides were seen in only ¢ve of 18 patients (28%), and no patients displayed ratios of greater than 2.0,
corresponding to an absence of CTL reactivity to MART-1 and tyrosinase antigens in our patient population.
dNot determined. Reactivity of patient 42 to gp100 peptides could not be determined due to inadequate serum sample; therefore, only reactivity to MART-1 and
tyrosinase is depicted for this patient.
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patients was classi¢ed as ‘‘inactive’’. A positive association was noted
between disease activity and T cell reactivity to gp100 peptides
(one-sided Wilcoxon rank-sum test, p¼ 0.0238). The signi¢cance
of this ¢nding is unclear, given that the number of patients with
inactive disease was small (six), and two of these patients were
noted to have ratios of greater than 3; however, the fact that the
p-value was signi¢cant despite the small sample size makes the
result noteworthy and suggests that this may be a true e¡ect.
Other autoimmune disease and T cell reactivity to
melanocyte peptides Five of 18 (28%) HLA-A2 vitiligo
patients were classi¢ed as having comorbid autoimmune disease
at the time of assessment. No association was noted between the
presence of comorbid autoimmune disease and Tcell reactivity to
gp100 (two-sidedWilcoxon rank-sum test, p¼ 0.5058). Similarly,
no association was noted between disease activity and T cell
reactivity to MelanA/MART-1 (two-sided Wilcoxon rank-sum
test, p¼ 0.1266) or tyrosinase (two-sided Wilcoxon rank-sum
test, p¼ 0. 1876) peptides.
DISCUSSION
In this study we have demonstrated an increase in the frequency
of antigen-speci¢c CD8þ T cells present in the circulation of
HLA-A2-positive vitiligo patients exhibiting reactivity to the
modi¢ed gp100 peptide epitopes. This reactivity appears to corre-
late with the patient’s active disease state and further supports the
notion that there is a cell-mediated component of disease pro-
gression. Reactivity to gp100 was detected ex vivo in 88% of
study patients and, in some instances, was marked, with T cell
IFN-g response reaching 42 times control, at levels comparable
with those seen with the common recall antigens, CMV and
Flu. The ability to detect peptide-speci¢c responses ex vivo with-
out an in vitro culture step more closely re£ects a truer measure-
ment of an active recall response to previous encountered antigen.
Overall, these ¢ndings indicate a clear association between
CD8þ T lymphocyte reactivity to melanocyte gp100 and vitili-
go, suggesting a pathogenic role for gp100-speci¢c T cells in this
disease.
CD8þ T lymphocyte reactivity to MelanA/MART-1 peptide
ex vivo was not seen in this vitiligo patient population, although
28% of patients did demonstrate low levels of reactivity, with
ratios between 1.0 and 2.0. Moreover, signi¢cant reactivity to
MelanA/MART-1 was seen in only a single patient (patient 49)
after in vitro re-stimulation. These ¢ndings suggest that, whereas
Figure1. Ex vivo ELISPOTassay for IFN-c speci¢cTcell
responses in vitiligo patients. Patient PBMC (1105 per
well) were cultured on ELISPOT plates with 10 mg per mL of
each peptide overnight and developed the next day. A combi-
nation of the peptides from CMV and Flu, combinations of
the modi¢ed gp100 peptides, 209.2m and 280.9v, or MelanA-
MART-1, or tyrosinase, or HIV peptide as a control were
added to each of the appropriate wells. Each group was set up
in triplicate.
Figure 2. Ex vivo gp100 responses in normal donor PBMC. PBMC
(1105 per well) from healthy donors were incubated overnight with the
combination of the modi¢ed gp100 peptides, 209.2m and 280.9v, or CMV
peptide or HIVpeptide as a control. IFN-g spots were detected as described
in Materials and Methods. Each group was set up in triplicate.
Figure 3. In vitro re-stimulation of PBMC from vitiligo patients.
PBMC were harvested from bulk cultures at day 9 and reseeded on
IFN-g coated ELISPOT plates at 1105 cells per well. Bulk cultures that
have been stimulated with tyrosinase peptide were restimulated in triplicate
wells with tyrosinase peptide and HIV peptide as a control. Bulk cultures
stimulated with MelanA/MART-1 were restimulated in triplicate wells
with MelanA/MART-1 peptide and HIV peptide as a control. Peptides
were added at a ¢nal concentration of 10 mg per mL to the appropriate
wells. Plates were incubated overnight and then developed as described in
the Materials and Methods section.
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reactivity to MelanA/MART-1 may exist in vitiligo patients, it
occurs at low levels and in a minority of our cohort of patients.
In addition, previous studies have demonstrated that through re-
peated antigen-speci¢c stimulation in vitro, tyrosinase- and Mela-
nA/MART-1-speci¢c CTL may be generated from normal
controls (Visseren et al, 1995). These CTL have the functional ca-
pacity to lyze melanoma target cells (Visseren et al, 1995). Our
¢ndings stand in contrast with those of previous studies, which
have implicated MelanA/MART-1 as an important CTL target
in vitiligo and found little evidence of T cell reactivity to gp100
in the disease. Ogg et al (1998) demonstrated high frequencies of
circulating MelanA/MART-1-speci¢c cytotoxic T lymphocytes
in seven of nine HLA-A2-positive individuals with vitiligo using
HLA-peptide tetrameric complexes. Palermo et al (2001) also used
HLA-melanocyte peptide tetramers to stain PBMC ex vivo from
nine HLA-A2-positive vitiligo patients and noted high numbers
of both MelanA/MART-1- and tyrosinase-speci¢c T cells in all
patients. In contrast, no gp100-speci¢c T cells were detected ex
vivo in any patient, and enrichment of gp100 CD8þ/tetramerþ
T cells was achieved after in vitro re-stimulation in cell lines de-
rived from only one of four patients. Lang et al (2001) used the
ELISPOT assay to identify reactive CD8þ T cells with ¢ve pep-
tides from gp100, four peptides from MelanA/MART-1, and two
peptides from tyrosinase. In these studies melanocyte-speci¢c re-
active CD8þ T lymphocytes were found in 11 of 32 HLA-A2
vitiligo patients (43%).Tcells were predominantly directed against
MelanA/MART-1 epitopes (34% of patients) with reactivity to
gp100 epitopes occurring in only three of 32 (9%) of patients.
A number of factors may account for the discrepancy between
our ¢ndings and those of the studies previously described. First,
with regards to the higher level of reactivity to MelanA/MART-
1 noted in prior studies, both Ogg et al (1998) and Palermo et al
(2001) used an analog of the MelanA/MART-126^35 peptide mod-
i¢ed to increase binding a⁄nity to HLA-A2 (ELAGIGILTV (Val-
mori et al, 1998)) in constructing tetramers, whereas we used an
unmodi¢ed epitope AAGIGILTV (Coulie et al, 1994). Moreover,
Ogg et al (1998) included a round of in vitro re-stimulation to aid
in the expansion of potential peptide-speci¢c CD8 T cells. Lang
et al (2001) in their study tested both modi¢ed and unmodi¢ed
MelanA/MART-1 peptides. Reactivity to ELAGIGILTV was
seen in 34% of patients, whereas AAGIGILTV elicited a response
in only two of 32 (6%) of patients, which is in keeping with our
¢ndings.The lower level of reactivity to MelanA/MART-1 noted
in this study and in Lang et al (2001) may relate to the possible
presence of nonreactive melanocyte-speci¢c T cells in vitiligo pa-
tients. Such cells have been demonstrated in melanoma patients
(Lee et al, 1999) and would be identi¢able with tetramer staining
but not in IFN-g ELISPOT assay. We employed the modi-
¢ed gp100 peptides 209.2m and 280.9v (IMDQVPSFV and
YLEPGPVTV, respectively) (Parkhurst et al, 1996), to test the
CD8þ T lymphocyte response, which may explain the high level
of T cell reactivity to gp100 in our study. A recent study (Lang
et al, 2001) tested reactivity to ¢ve unmodi¢ed gp100 peptides,
which would be expected to generate a lesser T cell response,
whereas another study (Palermo et al, 2001) used the modi¢ed
gp100 209.2m peptide and noted only occasional presence of
gp100-speci¢c cytotoxicT lymphocytes in vitiligo patients; how-
ever, the majority of these patients had stable vitiligo, unlike our
study wherein most patients had active disease. In addition, the
combination of gp100 peptides in our study may have resulted
in additive e¡ects and higher ratios than might be seen with as-
says involving only single peptides. This is a potential limitation
of this study, as it is possible that the inclusion of other identi¢ed
peptide epitopes from MelanA/MART-1 or tyrosinase may have
revealed higher ratios of reactivity; however, given that the ma-
jority of gp100 ratios that we derived were many times greater
than those found for MelanA/MART-1 and tyrosinase, and given
that the overall reactivity to MelanA-MART-1 and tyrosinase
was undetectable in most instances, we feel that the observed re-
activity to gp100 is a true phenomenon. Finally, a variable re-
sponse to di¡erent epitopes of a given antigen may occur among
patients in general, as is seen in previous work (Lang et al, 2001). If
alternative MelanA/MART-1 and tyrosinase epitopes had been
included, we might have found reactivity to these antigens. Taken
together, our results and those described using modi¢ed epitopes
may reveal previous unseen reactivity to de¢ned melanocyte
antigens. This raises the possibility of using the modi¢ed forms
of the dominant Tcell epitopes to monitor anti-melanocyte reac-
tivity in melanoma patients receiving antigen-speci¢c vaccines.
CD8þ T lymphocyte reactivity to tyrosinase was not demon-
strated ex vivo in our patient population and was seen in only one
patient following in vitro re-stimulation. This is similar to what
was reported previously (Ogg et al, 1998), in studies that noted
no tyrosinase-speci¢c cytotoxic T lymphocytes in nine of
nine vitiligo patients using the same epitope of tyrosinase
(YMDGTMSQV (Skipper et al, 1996)) tetramers. One report
(Palermo et al, 2001), however, utilizing a di¡erent epitope
(MLLAVLYCL), found high frequencies of tyrosinase-speci¢c T
cells in nine of nine HLA-A2-positive vitiligo patients studied.
Studies (Lang et al, 2001) that examined two epitopes of tyrosi-
nase (MLLAVLYCL and YMNGTMSQV (Wolfel et al, 1994) and
noted weak reactivity in one of 32 patients to the former and
variable reactivity in four of 32 patients to the latter, again sug-
gesting that the CD8þ T lymphocyte response to tyrosinase is
heterogeneous.
We have noted a positive correlation between vitiligo disease
activity and reactivity to gp100. The fact that our ¢nding was sta-
tistically signi¢cant despite the small sample size supports the no-
tion that this is a true e¡ect. Our ¢nding is in keeping with that
of Lang et al (2001), who evaluated patients who had had progres-
sion of vitiligo within the previous 6 mo and who also found a
higher level of reactivity among patients with ‘‘actively progres-
sive’’disease (i.e., 10% or higher increase in vitiliginous lesions in
the last 3 mo) than among those with ‘‘moderately progressive’’
Table II. In vitro re-stimulation of HLA-A2þ vitiligo patients’ PBMC with MelanA/MART-1 and tyrosinase peptidesa
Peptide-speci¢c CTL reactivity
Spots/1105 PBMC Spots/1105 PBMC
Patient MART-1 Control MART-1 ratiob Tyrosinase Control Tyrosinase ratiob
37 39.7 28.3 1.4 5.3 7.7 0.7
40 2 1.7 1.2 16.3 17.3 0.94
49c 86 6.3 13.58 43.3 5.0 8.67
55 31 44.3 0.7 1.3 0.3 4.3
aIn vitro re-stimulation of PBMC from vitiligo patients. PBMC were cultured for 9 d with either tyrosinase369^377 or MelanA/MART127^35. Cells were harvested and
added to ELISPOT plates with either stimulating peptide or HIV control peptide. Plates were developed the next day.
bRatios were derived by dividing the number of spots generated to test peptides on ELISPOT assay by the number of spots generated to HIV control peptide.
cNote the emergence of CTL reactivity in patient 49 to both MART-1 and tyrosinase peptides with in vitro restimulation.
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disease (i.e., less increase but signs of progression in the last 6
mo). Moreover, they observed a decrease in T cell reactivity in
patients whose disease became stable. Similar results were ob-
served revealing the lowest frequencies of MelanA/MART-1-
speci¢c T lymphocytes among patients with stable disease (Ogg
et al, 1998). The relationship between disease activity and melano-
cyte-speci¢cT lymphocyte frequency and reactivity lends further
support to the hypothesis that these cytotoxic lymphocytes play
an important part in causing melanocyte damage in vitiligo.
A family history of the disease was seen in 78% (14 of 18) of
our patients, which greatly exceeds the prevalence of 25 to 33%
reported in the literature (Majumder et al, 1993; Kovacs, 1998).This
is interesting in light of the fact that relatives of vitiligo patients
have been shown to have an increased frequency of serum auto-
antibodies and autoimmune reactivity (Mandry et al, 1996). It is
possible that the high level of reactivity to gp100 noted in this
study may relate to the relatively large number of our patients
with a positive family history of vitiligo; such patients may repre-
sent a subset of vitiligo patients with a higher level of immunor-
eactivity to certain melanocyte antigens. Another possible
explanation for the high prevalence of a positive family history
of vitiligo in our patients is our inclusion of second and third
degree relatives in the tally. Studies indicate that vitiligo is not
transmitted as an autosomal dominant or recessive trait but rather
as a polygenic trait (Majumder et al, 1993); thus, the inclusion
of more distant relatives in the de¢nition of family history is
appropriate.
It is noteworthy that 67% (18 of 27) of patients initially
screened were HLA-A2 positive. This HLA-A subtype is gener-
ally expressed in 35 to 45% of the population (Ellis et al, 2000).
Whereas our sample size is small and the noted higher prevalence
may have occurred due to chance, other studies have also ob-
served an increase in HLA-A2 expression among vitiligo patients
(Schallreuter et al, 1993; Buc et al, 1996). Associations with other
HLA class I and II subtypes have also been identi¢ed (Kemp et al,
2001; Kovacs, 1998), and comparative analysis of published data on
a possible association of HLAwith vitiligo does not support a de-
¢nitive linkage thus far (Schallreuter et al, 1993); however, the ob-
served overrepresentation of the HLA-A2 haplotype among
vitiligo patients suggests that antigen-speci¢c T cell reactivity to
HLA-A2-restricted melanocyte epitopes such as gp100 may serve
as the predominant mechanism in vitiligo pathogenesis. In this
regard, HLA-A2 expression may predispose to autoimmune dis-
orders. It may also confer resistance to certain diseases, as is the
case with melanoma, where the anti-melanocyte response of viti-
ligo is associated with improved prognosis (Nordlund et al, 1983;
Bystryn et al, 1987).
Our ¢ndings may have implications for the development of
immunotherapies for vitiligo and melanoma. If the dominant
epitopes that mediate autoimmune diseases such as vitiligo are
identi¢ed, it is possible to design therapies to treat this disease
with antagonist peptide ligands that could block speci¢c T cell
responses. Similarly, induction or augmentation of T cell re-
sponses to dominant melanocyte peptide antigens to produce vi-
tiligo might constitute an e¡ective therapy for melanoma. We
have demonstrated that by using the modi¢ed forms of the im-
munodominant melanocyte epitopes, responses can be detected
that reach levels of reactivity seen with common recall antigens.
Previous studies have shown that among melanoma patients re-
ceiving immunotherapy, de¢nitive anti-tumor responses occur
with high levels of circulating antigen-speci¢c CD8þ T cells
(Rosenberg et al, 1996; Pittet et al, 1999).
In summary, we have found evidence of an association be-
tween CD8þ T lymphocyte reactivity to the melanocyte antigen
gp100, and to a lesser extent MelanA/MART-1, and vitiligo.
Furthermore, we have noted that disease activity appears to cor-
relate with reactivity to gp100. Our ¢ndings support the concept
of an immunopathologic mechanism in vitiligo, in which cell-
mediated responses to normal melanocyte antigens play a crucial
part. Further studies are needed to delineate the speci¢cities of
CTL and their precise role in vitiligo and to advance our under-
standing and improve our ability to manage this disease.
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